Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrochlorothiazide/valsartan - Novartis

Drug Profile

Hydrochlorothiazide/valsartan - Novartis

Alternative Names: Co-Dio; Co-Diovan; Co-Tareg; CoDiovan; Covals; Diovan HCT; KODIO EX; KODIO MD; Miten Plus; Nisisco; Provas comp; VAH631; Valsartan HCT; Valsartan/hydrochlorothiazide - Novartis

Latest Information Update: 04 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Branched-chain amino acids; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 04 Feb 2019 Chemical structure information added
  • 18 Nov 2011 Generic equivalent available in Austria, Germany, Denmark, Ireland, Italy, Netherlands, Sweden & France
  • 15 Nov 2011 Generic equivalent available in the UK for heart failure, hypertension and myocardial infarction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top